Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2
Terminated
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
- Interventions
- Biological: AllopurinolBiological: Allogeneic natural killer cellsRadiation: total-body irradiationBiological: Aldesleukin
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 14
- Registration Number
- NCT00652899
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
Phase 1
Terminated
- Conditions
- Leukemia
- Interventions
- Radiation: yttrium Y 90 anti-CD19 monoclonal antibody BU12Radiation: 111In-BU-12
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT00643240
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Reduced Intensity AlloTransplant For Osteopetrosis
Phase 2
Terminated
- Conditions
- Osteopetrosis
- Interventions
- Procedure: Stem Cell or Umbilical Cord Blood TransplantationProcedure: Total Lymphoid Irradiation
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT00638820
- Locations
- 🇺🇸
University of MInnesota, Fairview, Minneapolis, Minnesota, United States
Intrathecal Enzyme Replacement for Hurler Syndrome
Phase 1
Completed
- Conditions
- Hurler Syndrome
- Interventions
- Drug: IRT Laronidase
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 26
- Registration Number
- NCT00638547
- Locations
- 🇺🇸
University of Minnesota, Fairview, Minneapolis, Minnesota, United States
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimProcedure: bone marrow transplantationProcedure: hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00630565
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
Phase 1
Completed
- Conditions
- Fanconi Anemia
- Interventions
- Biological: Anti-Thymocyte GlobulinProcedure: Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 31
- Registration Number
- NCT00630253
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
Phase 1
Completed
- Conditions
- Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT00625092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1
Terminated
- Conditions
- LeukemiaLymphoma
- Interventions
- Biological: aldesleukinBiological: allogeneic natural killer cellsBiological: rituximab
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00625729
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Lung CancerBreast CancerColorectal CancerHead and Neck CancerKidney CancerPancreatic CancerSarcomaUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: cetuximab
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 37
- Registration Number
- NCT00622674
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
MT2004-30: Tomotherapy for Solid Tumors
Phase 1
Terminated
- Conditions
- SarcomaBrain and Central Nervous System TumorsKidney CancerLiver CancerRetinoblastoma
- Interventions
- Biological: filgrastimProcedure: stem cell transplantationRadiation: tomotherapyRadiation: total marrow irradiationRadiation: Whole lung radiation
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath